Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III, Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Assess the Efficacy and Safety of Tocilizumab in Subjects With Giant Cell Arteritis

Trial Profile

A Phase III, Multicenter, Randomized, Double-Blind Placebo-Controlled Study to Assess the Efficacy and Safety of Tocilizumab in Subjects With Giant Cell Arteritis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 06 Jun 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tocilizumab (Primary) ; Corticosteroids; Methotrexate; Prednisone
  • Indications Giant cell arteritis
  • Focus Registrational; Therapeutic Use
  • Acronyms GiACTA
  • Sponsors Genentech; Roche
  • Most Recent Events

    • 06 Jun 2020 Results assessing immunogenicity in patients with giant cell arteritis treated with tocilizumab, presented at the 21st Annual Congress of the European League Against Rheumatism.
    • 06 Jun 2020 Results presented at the 21st Annual Congress of the European League Against Rheumatism
    • 06 Jun 2020 Results of this post-hoc analysis assessing the efficacy of adjunctive MTX in patients with GCA presented at the 21st Annual Congress of the European League Against Rheumatism
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top